Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2026 | $22.00 | Buy | B. Riley Securities |
| 4/21/2025 | $6.00 | Buy | Guggenheim |
| 4/4/2024 | $9.00 | Overweight | Piper Sandler |
| 8/9/2021 | $13.50 | Buy | Roth Capital |
8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
S-3 - Unicycive Therapeutics, Inc. (0001766140) (Filer)
SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
B. Riley Securities initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $22.00
Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00
Piper Sandler initiated coverage of Unicycive Therapeutics with a rating of Overweight and set a new price target of $9.00
U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities continue in anticipation of the potential commercial launch of OLC MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. "As we approach the June 29th PDUFA target action date, we remain opti
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 3:45 p.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investi
Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D
4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
4 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
U.S. Food and Drug Administration (FDA) review of oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission remains on track, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities continue in anticipation of the potential commercial launch of OLC MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. "As we approach the June 29th PDUFA target action date, we remain opti
Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D
- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders - Ended Q3 with $42.7 million of cash with expected runway into 2027 LOS ALTOS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for t
LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh
LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal
SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)